United States Surgical Generators Market Outlook to 2023
April 2017
79
About the Report
About the Report
United States Surgical Generators Market Outlook to 2023
Summary
GlobalData's new report, "United States Surgical Generators Market Outlook to 2023", provides key market data on the United States Surgical Generators market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) within market segments-Argon Plasma Coagulation Generators, Electrosurgical RF Generators, Electrocautery Generators and Ultrasonic Generators.
The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.
Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.
Scope
Market size and company share data for Surgical Generators market segments-Argon Plasma Coagulation Generators, Electrosurgical RF Generators, Electrocautery Generators and Ultrasonic Generators.
Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
2016 company shares and distribution shares data for each of the market segments.
Global corporate-level profiles of key companies operating within the United States Surgical Generators market.
Key players covered include Olympus Corporation, Medtronic plc, B. Braun Melsungen AG and Others.
Reasons to Buy
Develop business strategies by identifying the key market segments poised for strong growth in the future.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.
Products
Companies
Medtronic Plc, Olympus Corporation, B. Braun Melsungen AG, ConMed Corporation, ERBE Elektromedizin GmbH
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Surgical Generators Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Surgical Generators Market, United States 7
3.1 Surgical Generators Market, United States, Revenue ($m), 2009-2016 7
3.2 Surgical Generators Market, United States, Revenue ($m), 2016-2023 9
3.3 Surgical Generators Market, United States, Volume (Units), 2009-2016 11
3.4 Surgical Generators Market, United States, Volume (Units), 2016-2023 13
3.5 Surgical Generators Market, United States, Average Price ($), 2009-2023 15
3.6 Surgical Generators Market, United States, Distribution Share by Revenue ($m), 2016 17
3.7 Surgical Generators Market, United States, Company Share by Revenue ($m), 2016 18
4 Overview of Key Companies in United States, Surgical Generators Market 20
4.1 Medtronic Plc 20
4.1.1 Company Overview 20
4.2 Olympus Corporation 20
4.2.1 Company Overview 20
4.3 B. Braun Melsungen AG 20
4.3.1 Company Overview 20
4.4 ConMed Corporation 20
4.4.1 Company Overview 20
4.5 ERBE Elektromedizin GmbH 21
4.5.1 Company Overview 21
5 Financial Deals Landscape 22
5.1 Acquisition 22
5.1.1 Ethicon Endo-Surgery Acquire Megadyne Medical Products 22
5.1.2 Boston Scientific Acquires EndoChoice for USD210 Million in Tender Offer 23
6 Recent Developments 25
6.1 Corporate Communications 25
6.1.1 Mar 06, 2017: AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs 25
6.1.2 Jan 24, 2017: Bovie Medical Appoints Eminent Gynecologic Oncologist to Medical Advisory Board 25
6.1.3 Jan 09, 2017: Cutera Names James A. Reinstein as its Next President and CEO 26
6.1.4 Nov 11, 2016: AtriCure Names Sven Wehrwein to its Board of Directors 26
6.1.5 Nov 03, 2016: Cutera Elects J. Daniel Plants as Chairman of the Board 27
6.1.6 Aug 18, 2016: Cutera Announces Management Changes 27
6.1.7 May 02, 2016: EndoChoice Announces William Enquist as New Chairman of the Board 27
6.2 Financial Announcements 28
6.2.1 Mar 09, 2017: Bovie Medical Reports Fourth Quarter and Full Year 2016 Results 28
6.2.2 Mar 06, 2017: US FDA Approves Serenity Pharmaceuticals Noctiva (desmopressin acetate)-the First Drug Approved for the Treatment of Nocturia 29
6.2.3 Feb 28, 2017: AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results 30
6.2.4 Feb 13, 2017: Cutera Reports Fourth Quarter and Full-Year 2016 Record Revenue and Financial Results 31
6.2.5 Feb 08, 2017: Encision Reports Third Quarter Fiscal Year 2017 Results; Sequential Quarterly Revenue Grows 4 Percent 32
6.2.6 Feb 01, 2017: CONMED Announces Fourth Quarter and Fiscal Year 2016 Financial Results 32
6.2.7 Jan 31, 2017: UTMD Reports Audited Financial Performance for Fourth Quarter and Year 2016 34
6.2.8 Jan 24, 2017: Intuitive Surgical Announces Fourth Quarter Earnings 38
6.2.9 Jan 11, 2017: Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2016 Results 39
6.2.10 Jan 09, 2017: AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016 39
6.2.11 Jan 09, 2017: Cutera Announces Record Revenue and Preliminary Financial Results for Fourth Quarter and Full Year 2016 40
6.2.12 Nov 07, 2016: Cutera Reports Record Third Quarter 2016 Results 41
6.2.13 Nov 03, 2016: Encision Reports Second Quarter Fiscal Year 2017 Results 41
6.2.14 Oct 27, 2016: AtriCure Reports Third Quarter 2016 Financial Results 42
6.2.15 Oct 27, 2016: CONMED Announces Third Quarter 2016 Financial Results 42
6.2.16 Oct 26, 2016: Bovie Medical Reports 2016 Third Quarter and Nine Month Results 43
6.2.17 Oct 25, 2016: Utah Medical Products Reports Financial Performance for Third Quarter 2016 45
6.2.18 Oct 18, 2016: Intuitive Surgical Announces Third Quarter Earnings 48
6.2.19 Oct 11, 2016: Cutera Announces Preliminary Record Third Quarter 2016 Revenue 49
6.2.20 Aug 16, 2016: GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack 49
6.2.21 Aug 04, 2016: AtriCure Reports Second Quarter 2016 Financial Results 50
6.2.22 Aug 03, 2016: EndoChoice Announces Second Quarter 2016 Financial Results 51
6.2.23 Aug 02, 2016: Encision Reports First Quarter Fiscal Year 2017 Results 52
6.2.24 Aug 01, 2016: Cutera Reports Second Quarter 2016 Results 52
6.2.25 Aug 01, 2016: Bovie Medical Reports Second Quarter and First Half 2016 Results 53
6.2.26 Jul 27, 2016: CONMED Announces Second Quarter 2016 Financial Results 54
6.2.27 Jul 26, 2016: Utah Medical Products Reports Financial Performance for Second Quarter 2016 55
6.2.28 Jul 19, 2016: Intuitive Surgical Announces Second Quarter Earnings 58
6.2.29 Jun 02, 2016: Fuel3D announces first enterprise client scanning solution 59
6.2.30 May 13, 2016: Encision Reports Fourth Quarter and Fiscal Year 2016 Results 60
6.2.31 May 11, 2016: Bovie Medical Reports First Quarter 2016 Results 61
6.2.32 May 04, 2016: EndoChoice Announces First Quarter 2016 Financial Results 62
6.2.33 Apr 27, 2016: CONMED Announces First Quarter 2016 Financial Results 63
6.2.34 Apr 26, 2016: Utah Medical Products Reports Financial Performance for First Quarter 2016 64
6.3 Legal And Regulatory 67
6.3.1 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 67
6.3.2 Jun 10, 2016: FDA Lifts All Remaining Shipping Restrictions at Terumo Cardiovascular Systems' Ann Arbor Facility 67
6.4 Other Significant Developments 68
6.4.1 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 68
6.4.2 Jul 21, 2016: Bovie Medical Announces Sales Channel Partnership Agreement with Hologic for J-Plasma 68
6.4.3 Apr 21, 2016: Interim results from DIAGNODE-1 indicate clear and desired re-balancing of the immune system after administration of Diamyd directly into lymph nodes 69
6.4.4 Apr 11, 2016: New Study Data Show OpGen's QuickFISH Blood Culture Pathogen ID Tests to be Rapid and Cost-Effective, with Utility to Inform Antimicrobial Stewardship Decisions 71
6.5 Strategy And Business Planning 72
6.5.1 Feb 01, 2017: Bovie Medical Confirms Its 2017 Outlook 72
7 Appendix 73
7.1 Research Methodology 74
7.1.1 Coverage 74
7.1.2 Secondary Research 74
7.1.3 Primary Research 75
7.1.4 Market Modeling and Forecasting 76
7.1.5 Company Share Analysis 77
7.1.6 Distribution Share Analysis 78
7.1.7 Benchmarking 78
7.2 GlobalData Consulting 78
7.3 Contact Us 79
7.4 Disclaimer 79
List of Figure
1.2 List of Figures
Figure 1: Surgical Generators Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 7
Figure 2: Surgical Generators Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 9
Figure 3: Surgical Generators Market, United States, Volume (Units), Historic, 2009-2016 11
Figure 4: Surgical Generators Market, United States, Volume (Units), Forecast, 2016-2023 13
Figure 5: Surgical Generators Market, United States, Company Share (%) 2016 18
List of Table
1.1 List of Tables
Table 1: Surgical Generators Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 8
Table 2: Surgical Generators Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 10
Table 3: Surgical Generators Market, United States, Volume (Units), Historic, 2009-2016 12
Table 4: Surgical Generators Market, United States, Volume (Units), Forecast, 2016-2023 14
Table 5: Surgical Generators Market, United States, Average Price ($), Historic, 2009-2016 15
Table 6: Surgical Generators Market, United States, Average Price ($), Forecast, 2016-2023 16
Table 7: Surgical Generators Market, United States, Distribution Share by Revenue ($m), USD Constant, 2016 17
Table 8: Surgical Generators Market, United States, Company Share by Revenue ($m), USD Constant, 2016 19
Table 9: Ethicon Endo-Surgery Acquire Megadyne Medical Products 22
Table 10: Boston Scientific Acquires EndoChoice for USD210 Million in Tender Offer 23
Table 11: Total Number of Primary Research Participants, General Surgery Market, by Country 76
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.